Medtech startup Qure.ai has raised ₹543 crore in its Series D funding round, co-led by Lightspeed Venture Partners and 360 ONE Asset Management. This round also saw participation from the Merck Global Health Innovation Fund, Kae Capital, and existing investors such as Novo Holdings, HealthQuad, and TeamFund. The newly acquired capital will support Qure.ai’s expansion into the US and other international markets, enhance its GenAI foundation models, and fuel strategic acquisitions.

Founded in 2016 by Prashant Warier, Qure.ai focuses on using artificial intelligence to revolutionize medical imaging diagnostics. The company's AI-powered algorithms can detect critical abnormalities from X-rays, CT scans, and MRIs within minutes, typically taking doctors much longer. This advancement aims to tackle healthcare bottlenecks by offering faster, more accurate diagnoses.

"AI is transforming healthcare, from disease detection to patient management and even drug discovery," said Prashant Warier, co-founder and CEO of Qure.ai. "With the growing demand for faster diagnostics, AI is becoming a key player in reducing the workload on healthcare professionals and enhancing patient outcomes."

This funding arrives when India's medtech sector is witnessing rapid growth, driven by digital health and AI. Qure.ai is well-positioned to lead this transformation, building on its success and further pushing the boundaries of AI in healthcare.